focus -WSS

focus

author：Wikipedia 2025-08-29 19:53:59 - browse：4

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： 6 phony surgeries that take placebo to the extreme

hotspot

entertainment

WSS

Hormonal contraceptives don’t actually treat endometriosis

Are infertility treatments 'essential' during the Covid

In rare move, senator releases unverified FBI source report alleging Biden bribe

Judge denies Trump's request for new trial in E. Jean Carroll case

The Harvard botanist who searched for psychedelics in the Amazon

Judge denies Trump's request for new trial in E. Jean Carroll case

Wikipedia

focus

explore

BioMarin wins approval for gene therapy to treat hemophilia A

A new nitrogen execution bill also undermines medical licensing

Moonlake's readout produced a cash windfall. Risks remain

Judge denies Trump's request for new trial in E. Jean Carroll case

Drug repurposing or repositioning? The language matters

Stanford president’s abrupt resignation sparks debate

Bright Health sells Medicare Advantage business to Molina

Caribou posts encouraging results on off

The cancer drug shortage isn’t new — and neither are the solutions

A solution to the after

focus

PBM reform efforts get punted in Congress

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

6 phony surgeries that take placebo to the extreme

New documents shed light on MD Anderson Cancer Institute feud

hotspot

entertainment

hotspot

focus